Valmark Advisers Inc. Has $375,000 Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Valmark Advisers Inc. raised its stake in Edwards Lifesciences Co. (NYSE:EW) by 20.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 4,917 shares of the medical research company’s stock after buying an additional 825 shares during the quarter. Valmark Advisers Inc.’s holdings in Edwards Lifesciences were worth $375,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of EW. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its stake in shares of Edwards Lifesciences by 440.0% in the third quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company’s stock worth $243,173,000 after purchasing an additional 2,860,000 shares during the last quarter. AustralianSuper Pty Ltd purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth approximately $168,519,000. Nordea Investment Management AB raised its stake in shares of Edwards Lifesciences by 1,224.1% in the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after purchasing an additional 1,488,791 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Edwards Lifesciences by 9.2% in the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock worth $1,138,575,000 after purchasing an additional 1,390,427 shares during the last quarter. Finally, FMR LLC raised its stake in shares of Edwards Lifesciences by 61.1% in the third quarter. FMR LLC now owns 3,111,385 shares of the medical research company’s stock worth $215,557,000 after purchasing an additional 1,179,637 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on EW shares. Morgan Stanley upped their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, March 21st. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Piper Sandler increased their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a report on Friday. Finally, Wells Fargo & Company increased their price objective on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $92.71.

Edwards Lifesciences Trading Down 1.8 %

Shares of EW stock opened at $86.43 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12. The company has a market capitalization of $52.02 billion, a PE ratio of 37.25, a price-to-earnings-growth ratio of 4.28 and a beta of 1.05. The business’s fifty day moving average is $90.28 and its 200 day moving average is $78.95.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. On average, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the firm’s stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.98, for a total transaction of $156,030.70. Following the sale, the vice president now owns 17,213 shares in the company, valued at $1,566,038.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Daniel J. Lippis sold 1,715 shares of Edwards Lifesciences stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the completion of the transaction, the vice president now owns 17,213 shares in the company, valued at approximately $1,566,038.74. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 194,004 shares of company stock worth $17,166,254. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.